Dr. Lal PathLabs’ Board of Directors approved the financial results for Q3 2026 and declared a third interim dividend of INR 3.5 per share. The company’s revenue from operations reached ₹6598 million. Additionally, the board approved the allotment of equity shares under the Employee Stock Option Plan.
Financial Performance
Dr. Lal PathLabs announced its unaudited consolidated financial results. Key highlights include:
- Revenue from operations: ₹6598 million for Q3 2026 (₹20,602 million year-to-date)
- Other income: ₹244 million for Q3 2026 (₹773 million year-to-date)
- Profit for the period: ₹914 million
Interim Dividend Declaration
The Board has declared a third interim dividend of INR 3.5 per equity share (at 35% on face value of INR 10 each) for the financial year 2025-26. The record date for payment is February 5, 2026. The dividend will be credited within 30 days of declaration.
ESOP Allotment
The Board approved the allotment of 4,000 equity shares under the Employee Stock Option Plan 2010. Consequently, the paid-up equity share capital of the Company increased to INR 1,67,55,50,200, divided into 16,75,55,020 equity shares of INR 10 each.
Subsidiary Updates
Suburban Diagnostics (India) Private Limited was voluntarily liquidated on February 11, 2025, with its business undertaking distributed to the Parent Company.
Dr. Lal PathLabs Kenya Private Limited was dissolved with effect from September 13, 2024.
Source: BSE
